November 13, 2020
PM Modi spoke on significantly higher levels of export for these ‘immunity boosting’ products during the pandemic period
PM Modi inaugurated two future-ready, premier ayurvedic institutions in Jamnagar and Jaipur
In 2018-19, the total export value of ayurvedic products amounted to US$446 million
Govt of India has budgeted over US$285 million for FY 2020-21 to modernise AYUSH formulations
The export of ayurveda products recorded a 45 per cent increase in September, as compared to the same period in the previous year, following the official adoption of AYUSH practices by the Centre as a means to manage and boost immunity against COVID-19, according to an announcement from Prime Minister Narendra Modi on November 13. PM Modi addressed audiences on growing interest worldwide for Indian spices and other ayurvedic solutions based on significantly higher levels of export for these ‘immunity boosting’ products. The virtual event was organised to inaugurate two future-ready, premier ayurvedic institutions, namely the Institute of Teaching and Research in Ayurveda (ITRA) in Jamnagar, and the National Institute of Ayurveda (NIA) in Jaipur, as per an official Ministry of Ayush release following the event.
In 2018-19, the total export value of ayurvedic products and herbal remedies amounted to US$446 million, showcasing a growing demand for these products in global markets and encouraging further research into the immunity boosting properties of ayurvedic medicines. Amid the COVID-19 crisis, India has been forwarding information on AYUSH to partner nations around the world. While promoting the benefits of traditional medicines, the Ministry of AYUSH has also been spreading awareness on misinformation and corruption related to traditional medicines to ensure best practices in the space.
Since 2014, the Government of India has been proactively promoting India’s rich heritage of traditional healthcare and medicines, which owing to its growing global demand has helped the nation strengthen ties with foreign nations. The Government has sought to standardize the formulations of these drugs and publish related pharmacopeias to boost confidence in traditional medicines and healthcare practices globally. By breathing a new lease of life into AYUSH, India has attracted numerous key international partnerships across R&D, capacity building, trade, and investment. To drive future activities around AYUSH, the Government of India has budgeted over US$285 million for FY 2020-21 to modernise AYUSH formulations while building new institutions to expand capacity.